Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.

"Conflicts of interest G.D.H. reports research support from Alimentiv, Bühlmann Laboratories, Eli Lilly, Johnson & Johnson, Prometheus, Pfizer and Takeda; lecture fees from AbbVie, Eli Lilly, Johnson & Johnson, Pfizer, Takeda and Tillotts; consulting fees from AbbVie, Alimentiv, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Galapagos, Immunic, Johnson & Johnson, Protagonist, Pfizer, Samsung Bioepis, Takeda, Tillotts and Ventyx. F.B. reports grant/research support from AbbVie, Amgen, Janssen and Takeda; honoraria from AbbVie, Amgen, Arena, Celgene, Celltrion, Ferring, Fresenius Kabi, Janssen, Merck Sharp & Dohme, Pfizer, Sandoz and Takeda; and was on speaker bureaus for AbbVie, Arena, Ferring, Janssen, Merck Sharp & Dohme, Pfizer and Takeda. S.D. reports lecture fees from AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Hospira, Johnson & Johnson, Merck, Merck Sharp & Dohme, Mundipharma, Pfizer, Sandoz, Takeda, TiGenix, UCB and Vifor; consulting fees from AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Hospira, Johnson & Johnson, Merck, Merck Sharp & Dohme, Mundipharma, Pfizer, Sandoz, Takeda, TiGenix, UCB and Vifor. T.K. reports research support from AbbVie, Alfresa, Asahi Kasei Medical, EA Pharma, Kyorin, Mochida, Nippon Kayaku, Otsuka, Thermo Fisher Scientific and Zeria; consulting fees from AbbVie, Alfresa, Bristol Myers Squibb, Covidien, Eli Lilly, Ferring, Janssen, Kyorin, Mochida, Nippon Kayaku, Pfizer, Takeda and Thermo Fisher Scientific; lecture fees from AbbVie, Ajinomoto Bio-Pharma, Alfresa, Asahi Kasei Medical, Astellas, Celltrion, EA Pharma, Eisai, Gilead, Janssen, JIMRO, Kyorin, Mitsubishi Tanabe Pharma, Mochida, Nippon Kayaku, Takeda and Zeria. E.V.L. Jr reports research support from AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance Biopharma and UCB; consulting fees from AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Calibr, Celgene, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iterative Heatlh, Iota Biosciences, Janssen, KSL Diagnostics, Morphic Therapeutics, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Sun Pharma, Surrozen, Takeda and UCB; is a shareholder of Exact Sciences; and served as a medical editor for Healio/SLACK. W.J.S. reports research grants from AbbVie, Abivax, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, Janssen, Pfizer, Prometheus Biosciences, Seres, Shire, Takeda and Theravance Biopharma; consulting fees from AbbVie, Abivax, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Allakos, Amgen, Arena, AstraZeneca, Atlantic, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, ClostraBio, Eli Lilly, Forbion, Galapagos, Genentech (Roche), GlaxoSmithKline, Gossamer Bio, Index, Iota Biosciences, Janssen, Morphic, Novartis, Oppilan Pharma (now Ventyx Biosciences), Pfizer, Pharm-Olam, Polpharma, Progenity, Prometheus Biosciences, Protagonist, PTM, Seres, Shoreline Biosciences, Sublimity, Surrozen, Takeda, Theravance Biopharma, Vedanta Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences, Xencor and Zealand; stock or stock options from Allakos, BeiGene, Gossamer Bio, Oppilan Pharma (now Ventyx Biosciences), Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences and Vivreon Gastrosciences; and is an employee of Shoreline Biosciences. Spouse of W.J.S. reports being a consultant and holds stock/stock options in IVERIC Bio and Prometheus Laboratories; holds stock in Progenity and Oppilan Pharma (now Ventyx Biosciences); is an employee of and holds stock/stock options in Prometheus Biosciences; and holds stock/stock options in Ventyx Biosciences and Vimalan Biosciences. Q.D. is an employee of Cytel, subcontracted to Takeda at the time of the study. D.L., K.K. and E.G.M. are employees of and hold stock/stock options in Takeda. S.V. reports research support from AbbVie, Galapagos, Johnson & Johnson, Pfizer and Takeda; lecture fees from AbbVie, Centocor, Ferring, Genentech/Roche, Hospira, Johnson & Johnson, Merck Sharp & Dohme, Pfizer, Takeda and Tillotts; consulting fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Avaxia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CVasThera, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech-Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, Merck Sharp & Dohme, MiroBio, Morphic, MRM Health, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts and Zealand."

"This study was funded by Takeda."